--- title: "BAXTER INTERNATIONAL INC SEC 10-K Report" type: "News" locale: "en" url: "https://longbridge.com/en/news/275814169.md" description: "Baxter International Inc. has released its 2025 10-K report, highlighting a total net sales of $11.24 billion, a 6% increase from 2024. However, the company reported a net loss of $957 million, impacted by goodwill impairments and special items. Key strategic initiatives included the sale of its Kidney Care business for $3.80 billion and a new operating model to streamline operations. Baxter aims to optimize its capital structure and reduce debt while facing challenges from market conditions and financial volatility." datetime: "2026-02-12T21:55:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275814169.md) - [en](https://longbridge.com/en/news/275814169.md) - [zh-HK](https://longbridge.com/zh-HK/news/275814169.md) --- # BAXTER INTERNATIONAL INC SEC 10-K Report Baxter International Inc., a global leader in medical products and therapies, has released its 2025 10-K report, detailing significant financial performance, business operations, strategic initiatives, and the challenges faced over the past year. The report provides a comprehensive overview of the company's efforts to streamline operations, enhance product offerings, and navigate a complex market environment. **Financial Highlights** **Total Net Sales**: $11,244 million, an increase of 6% over 2024 on a reported basis and 3% on an operational sales basis. **Gross Margin**: $3,379 million, representing 30.1% of net sales, a decrease from 37.5% in 2024, primarily due to the impact of the Kidney Care MSA and unfavorable manufacturing variances. **Total Operating Income (Loss)**: $(308) million, compared to $14 million in 2024, impacted by goodwill impairments and special items. **Net Income (Loss) Attributable to Baxter Stockholders**: $(957) million, including special items which adversely impacted net income by $2.09 billion. **Diluted EPS**: $(1.87) per share, reflecting the impact of special items and restructuring costs. **Business Highlights** **Revenue Segments**: Baxter International Inc. manages its global operations based on three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The Medical Products & Therapies segment includes sterile IV solutions, infusion systems, and surgical hemostat products. Healthcare Systems & Technologies covers smart bed systems and patient monitoring technologies. Pharmaceuticals include specialty injectable pharmaceuticals and inhaled anesthetics. **Geographical Performance**: International sales totaled $5.12 billion in 2025, marking a 7% increase compared to 2024. Sales in the United States reached $6.12 billion, a 5% increase from the previous year. Emerging markets, including Eastern Europe, the Middle East, Africa, Latin America, and Asia (except Japan), saw a 3% increase in sales. **Sales Units**: The Medical Products & Therapies segment saw a 2% increase in net sales, with Advanced Surgery products experiencing a 9% growth driven by increased sales volume globally. The Healthcare Systems & Technologies segment reported a 4% increase in net sales, with Care and Connectivity Solutions growing by 5% due to increased capital spending by customers. **New Product Launches**: Baxter has been focusing on expanding its connected care portfolio, which includes smart bed systems, infusion pumps, and patient monitoring technologies. This is part of their innovation strategy to accelerate sales growth through new customer-centric offerings. **New Production Launches**: Baxter continued to invest in capital expenditures, totaling $513 million in 2025, to support future growth and improve production efficiency. These investments are aimed at enhancing quality systems and optimizing manufacturing capabilities. **Future Outlook**: Baxter is committed to driving sustainable growth and innovation, focusing on improving performance and fostering a culture of continuous improvement. The company plans to continue optimizing its portfolio and operational model to better align with commercial activities and respond effectively to market changes. **Strategic Initiatives** Baxter International Inc. undertook significant strategic initiatives, including the sale of its Kidney Care business to Carlyle Group Inc. for $3.80 billion, which was completed on January 31, 2025. This move was part of a broader strategy to streamline operations and focus on core business segments. Additionally, the company implemented a new operating model in the third quarter of 2023 to simplify operations and better align manufacturing and supply chain activities with commercial operations. The company also completed the sale of its BioPharma Solutions business in September 2023, receiving $3.96 billion in cash proceeds. In 2025, Baxter repaid $3.81 billion of legacy indebtedness, primarily using the net after-tax cash proceeds from the sale of its Kidney Care business. The company also issued $2.00 billion in new notes to refinance existing debt. Baxter maintained a multicurrency revolving credit facility with a maximum capacity of $2.20 billion, maturing in 2030, and had no borrowings outstanding under this facility as of December 31, 2025. The company paid $348 million in cash dividends to stockholders in 2025 and did not repurchase any shares under its existing share repurchase program, which had $1.30 billion remaining available as of December 31, 2025. Future Outlook: Baxter plans to continue optimizing its capital structure by reducing debt levels and exploring opportunities for capital investment to support growth. The company intends to pursue cost savings initiatives to mitigate dis-synergies from the sale of its Kidney Care business and further optimize its business and manufacturing footprint. Baxter's credit ratings were revised to BBB- by Standard & Poor's and Baa3 by Moody's, both with a stable outlook, reflecting the company's ongoing efforts to manage its financial position and leverage. **Challenges and Risks** The company faces significant risks related to its strategic actions, including the divestiture of its Kidney Care business and the acquisition of Hillrom. These actions have led to organizational changes and market exits, increasing vulnerability to market conditions and financial volatility. The company has yet to achieve its net leverage targets, constraining cash resources and growth initiatives. The company is burdened by substantial indebtedness, requiring significant cash flow for debt service, which limits investments in R&D and other growth strategies. Failure to meet net leverage targets by 2026 could lead to credit rating downgrades, increasing borrowing costs and reducing capital access. There is intense competition in the product markets, with risks of declining demand and pricing pressures. Competitors may respond more quickly to technological changes, potentially leading to loss of market share and reduced profitability. The company has experienced supply chain disruptions, including production delays, increased costs, and shortages of raw materials. These challenges, exacerbated by global economic conditions and inflation, have negatively impacted sales and may continue to do so. Management transitions have created uncertainties, with potential difficulties in attracting and retaining key employees, which could impact the company's ability to achieve financial and strategic objectives. Management acknowledges the challenges posed by global economic conditions, including inflation and currency fluctuations, which have adversely affected operations. The company is focused on achieving operating efficiencies and sustaining cost reductions but recognizes the risks associated with restructuring initiatives. The company is exposed to risks from incorporating AI and emerging technologies into its products and operations. There are uncertainties related to regulatory approvals, safety, and ethical implications, which could impact competitiveness and business prospects. The company is subject to foreign currency exchange rate fluctuations, which have affected the reported value of assets and liabilities. Interest rate changes and access to capital markets are also significant risks, with potential impacts on financial results and liquidity. Overall, the company is navigating a complex landscape of operational, market, and regulatory risks, with strategic initiatives aimed at mitigating these challenges and positioning for future growth. SEC Filing: BAXTER INTERNATIONAL INC \[ BAX \] - 10-K - Feb. 12, 2026 ### Related Stocks - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BAX.US](https://longbridge.com/en/quote/BAX.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) ## Related News & Research - [Edwards Lifesciences Insider Sold Shares Worth $2,000,193, According to a Recent SEC Filing](https://longbridge.com/en/news/287878668.md) - [GE HealthCare Technologies Director Purchased Shares Worth Over $642K](https://longbridge.com/en/news/287687028.md) - [Anvi Global Holdings Delays Annual 10-K Filing](https://longbridge.com/en/news/288123742.md) - [Hansa Biopharma’s ConfIdeS Phase 3 Kidney Data Secures Late-Breaking ATC Spotlight](https://longbridge.com/en/news/287542913.md) - [Director Of Stryker Sold $96.79M In Stock](https://longbridge.com/en/news/288089026.md)